Genmab — Juni 2017

[Bulder]

Fra Celgenes Q1 CC: Michael Pehl: An important near term growth driver in the U.S. will be the expected (min fremhævelse) FDA approval of POMALYST in combination with daratumumab for relapsed refractory myeloma by June of this year. https://seekingalpha.com/article/4066320-celgene-celg-q1-2017-results-earnings-call-transcript?part=single

[GeorgeBest]

Hold nu op Solsen. Vi kan læse herfra og til mandag aften. Det er squ for langhåret efter 3 glas rødvin

[bikube]

Så ramte JNJ lige kurs 130, der er ATH.Det ligner stor interesse for ASCO.

[Budweis]

Der kom også lidt liv i HALO her op til ASCO.

[Budweis]

ASCO kan følges på Twitter under #ASCO17

[Budweis]

Tidspunkterne for Genmabs præsentationer ligger på - http://files.shareholder.com/downloads/AMDA-KPIBN/4448022645x0x938217/26f665a4-b920-4cbc-adcd-0054c322da34/i03_ASCO_200417_uk.pdf

[Helge_LarsenPI-redaktør]

Super. Tak Bulder.

[Legolas23]

Tak og god morgen

[Budweis]

God morgen. (Chicago (ASCO) er 7 timer bagud)

[transalp]

: )
Go morgen..

[bibob]

God morgen og god pinse

[bibob]

NBI lukkede i + 1,69 %. Tegner godt.

[bibob]

GMXAY luk i ATH . 110.44. + 1,47%

[royal]

Og JNJ tæt på ATH

[Helge_LarsenPI-redaktør]

[gentogen]

Document Moved

(www.ascopost.com)

[gentogen]

Access Denied

(www.medpagetoday.com)

[gentogen]

ata suggest a previously unknown, multidimensional, immunomodulatory role for daratumumab that may contribute to deeper clinical responses and enhanced survival.

[gentogen]

an additional, previously uncharacterized mechanism of action of daratumumab through immunomodulation that may contribute to clinical responses and its efficacy i

[mobbyduck1]

super link!